

What is claimed is:

112 1st - scope of term enabled for 5- (Furuk)

1 1. A method for treating a patient having a disease associated with
2 undesirable or uncontrolled cell proliferation, the method comprising:
3 administering to the patient a 20(S)-camptothecin for a period of time
4 during which a [pyrimidine base analog] is not being administered to the patient;
5 and
6 administering a pyrimidine base analog to the patient.

in all occurrences no chemical formula or specific name provided 112 2nd

1 2. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 1 day before the pyrimidine base analog is administered.

1 3. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 2 days before the pyrimidine base analog is administered.

1 4. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 3 days before the pyrimidine base analog is administered.

1 5. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 4 days before the pyrimidine base analog is administered.

1 6. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 5 days before the pyrimidine base analog is administered.

1 7. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 1 and 90 days before the pyrimidine base analog is
3 administered.

1 8. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 2 and 90 days before the pyrimidine base analog is
3 administered.

1 9. A method according to claim 1 wherein the 20(S)-camptothecin

1001074-024020-4263001

10061974-022102
20120426T18001

2 is administered between 3 and 90 days before the pyrimidine base analog is
3 administered.

1 10. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 4 and 90 days before the pyrimidine base analog is
3 administered.

1 11. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 5 and 90 days before the pyrimidine base analog is
3 administered.

1 12. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 1 day after the pyrimidine base analog is administered.

1 13. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 2 days after the pyrimidine base analog is administered.

1 14. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 3 days after the pyrimidine base analog is administered.

1 15. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 4 days after the pyrimidine base analog is administered.

1 16. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 5 days after the pyrimidine base analog is administered.

1 17. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 1 and 90 days before or after the pyrimidine base analog
3 is administered and is also administered within 1 day of when the pyrimidine base
4 analog is administered.

1 18. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 2 and 90 days before or after the pyrimidine base analog
3 is administered and is also administered within 2 days of when the pyrimidine

10081974-022102
201220-42618001

4 base analog is administered.

1 19. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 3 and 90 days before or after the pyrimidine base analog
3 is administered and is also administered within 3 days of when the pyrimidine
4 base analog is administered.

1 20. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 4 and 90 days before or after the pyrimidine base analog
3 is administered and is also administered within 4 days of when the pyrimidine
4 base analog is administered.

1 21. A method according to claim 1 pancreatic cancer wherein the
2 pyrimidine base analog is a fluorinated analog of a pyrimidine base.

1 22. A method according to claim 1 pancreatic cancer wherein the
2 pyrimidine base analog is a fluorinated analog of uracil.

1 23. A method according to claim 1 wherein the 20(S)-camptothecin
2 is 9-nitro-20(S)-camptothecin.

1 24. A method according to claim 1 wherein the disease associated
2 with undesirable or uncontrolled cell proliferation is cancer.

1 25. A method according to claim 1 wherein [the cancer] is selected
2 from the group consisting of acute myelogenous leukemia, cholangiocarcinoma,
3 chronic myelogenous leukemia, lymphoma, melanoma, multiple myeloma,
4 osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung,
5 ovarian, pancreatic, prostate, and stomach cancer.

lacks
clear basis
not seen in
clm 1

1 26. A method according to claim 1 wherein the disease associated
2 with undesirable or uncontrolled cell proliferation is pancreatic cancer.

10081974-032402
20120426T1801

1 27. A method for treating a patient having a disease associated with
2 undesirable or uncontrolled cell proliferation, the method comprising:

3 administering to the patient a 20(S)-camptothecin for a period of time
4 during which a pyrimidine base analog is not present in a pharmacologically
5 active form in the patient's body; and administering a pyrimidine base analog to
6 the patient.

1 28. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 1 day before the pharmacologically active pyrimidine base
3 analog is present in the patient's body.

1 29. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 2 days before the pharmacologically active pyrimidine
3 base analog is present in the patient's body.

1 30. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 3 days before the pharmacologically active pyrimidine
3 base analog is present in the patient's body.

1 31. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 4 days before the pharmacologically active pyrimidine
3 base analog is present in the patient's body.

1 32. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 5 days before the pharmacologically active pyrimidine
3 base analog is present in the patient's body.

1 33. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 1 and 90 days before the pharmacologically active
3 pyrimidine base analog is present in the patient's body.

1 34. A method according to claim 27 wherein the 20(S)-camptothecin

2 is administered between 2 and 90 days before the pharmacologically active
3 pyrimidine base analog is present in the patient's body.

1 35. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 3 and 90 days before the pharmacologically active
3 pyrimidine base analog is present in the patient's body.

1 36. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 4 and 90 days before the period when the
3 pharmacologically active pyrimidine base analog is present in the patient's body.

1 37. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 5 and 90 days before the pharmacologically active
3 pyrimidine base analog is present in the patient's body.

1 38. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 1 day after the pharmacologically active pyrimidine base
3 analog is no longer present in the patient's body.

1 39. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 2 days after the pharmacologically active pyrimidine base
3 analog is no longer present in an active form in the patient's body.

1 40. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 3 days after the pharmacologically active pyrimidine base
3 analog is no longer present in an active form in the patient's body.

1 41. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 4 days after the pharmacologically active pyrimidine base
3 analog is no longer present in an active form in the patient's body.

1 42. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 5 days after the pharmacologically active pyrimidine base

3 analog is no longer present in an active form in the patient's body.

1 43. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 1 and 90 days before or after the pharmacologically
3 active pyrimidine base analog is present in the patient's body and is also
4 administered within 1 day of when the pharmacologically active pyrimidine base
5 analog is present in the patient's body.

1 44. A method according to claim ~~27~~ wherein the 20(S)-camptothecin
2 is administered between 2 and 90 days before or after the pharmacologically
3 active pyrimidine base analog is present in the patient's body and is also
4 administered within 2 days of when the pharmacologically active pyrimidine base
5 analog is present in the patient's body.

1 45. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 3 and 90 days before or after the pharmacologically
3 active pyrimidine base analog is present in the patient's body and is also
4 administered within 3 days of when the pharmacologically active pyrimidine base
5 analog is present in the patient's body.

1 46. A method according to claim ~~27~~ wherein the 20(S)-camptothecin
2 is administered between 4 and 90 days before or after the time when the
3 pharmacologically active pyrimidine base analog is present in the patient's body
4 and is also administered within 4 days of when the pharmacologically active
5 pyrimidine base analog is present in the patient's body.

1 47. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 5 and 90 days before or after the time when the
3 pharmacologically active pyrimidine base analog is present in the patient's body
4 and is also administered within 5 days of when the pharmacologically active
5 pyrimidine base analog is present in the patient's body.

1 48. A method according to claim 27 wherein the pyrimidine base

2 analog is a fluorinated analog of a pyrimidine base.

1 49. A method according to claim 27 wherein the pyrimidine base
2 analog is a fluorinated analog of uracil.

1 50. A method according to claim 27 wherein the 20(S)-camptothecin
2 is 9-nitro-20(S)-camptothecin.

1 51. A method according to claim 27 wherein the disease associated
2 with undesirable or uncontrolled cell proliferation is cancer.

1 52. A method according to claim 27 wherein the cancer is selected
2 from the group consisting of acute myelogenous leukemia, cholangiocarcinoma,
3 chronic myelogenous leukemia, lymphoma, melanoma, multiple myeloma,
4 osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung,
5 ovarian, pancreatic, prostate, and stomach cancer.

1 53. A method according to claim ~~27~~ wherein the disease associated
2 with undesirable or uncontrolled cell proliferation is pancreatic cancer.

*lacks clear
anto. basis.
from clm 27.*

10031974-022102
201220-42678001